3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Recruiting
1
Completed
1
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Myeloid
1
Conditions
Thrombocythemia, Essential
1
Primary Myelofibrosis
1
Polycythemia Vera
1
Leukemia, Myeloid, Acute
1
Interventions
ruxolitinib
4
Specimen Handling
2
Biopsy
2
11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene
2
talazoparib
1
poly ICLC
1
piperine
1
fludarabine phosphate
1
fludarabine
1
fedratinib
1
demethoxycurcumin
1
bomedemstat
1
X-Rays
1
Whole-Body Irradiation
1
Watchful Waiting
1
Tacrolimus
1
Stem Cell Transplantation
1
Positron-Emission Tomography
1
N(4)-oleylcytosine arabinoside
1
Mycophenolic Acid
1
Methotrexate
1
Melphalan
1
Injections
1
Hematopoietic Stem Cell Transplantation
1
Decitabine
1
Cyclophosphamide
1
Curcumin
1
Aspirin
1
Acetylcysteine
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Thrombocythemia, Essential
×
bomedemstat
×
Clear all
NCT06351631
2026-04-02
MK-3543-017
Merck Sharp & Dohme LLC
Phase 3
Recruiting
400 enrolled